Klaus Schmierer
Klaus Schmierer, MB BS PhD FRCP
Klaus Schmierer is a Reader in Clinical Neurology at The Blizard Institute, Barts and The London School of Medicine & Dentistry (Queen Mary University of London), and a Consultant Neurologist at The Royal London Hospital of Barts Health NHS Trust, where he is both the Research Lead for Neurology and Clinical Lead for BartsMS.
He serves on the Consortium for Progressive MS of the MS Society’s Clinical Trials Network, and the Advisory Board of the UK MS Register. He is also the Subspeciality Lead for MS at the National Institute of Health Research North Thames CRN. Dr Schmierer has been an advisor to the EMA, MHRA, and NICE on new drugs for MS.
Ever since starting his career in neurology, Dr Schmierer has maintained a clinical and experimental research focus on MS. His work includes research into the pathology, pathophysiology, MRI appearance and disease control in people with MS, the (differential) diagnosis & monitoring of MS, and investigator-led and commercial clinical trials. He advocates a pro-active treatment approach at all stages of MS.
Klaus Schmierer is a Reader in Clinical Neurology at The Blizard Institute, Barts and The London School of Medicine & Dentistry (Queen Mary University of London), and a Consultant Neurologist at The Royal London Hospital of Barts Health NHS Trust, where he is both the Research Lead for Neurology and Clinical Lead for BartsMS.
He serves on the Consortium for Progressive MS of the MS Society’s Clinical Trials Network, and the Advisory Board of the UK MS Register. He is also the Subspeciality Lead for MS at the National Institute of Health Research North Thames CRN. Dr Schmierer has been an advisor to the EMA, MHRA, and NICE on new drugs for MS.
Ever since starting his career in neurology, Dr Schmierer has maintained a clinical and experimental research focus on MS. His work includes research into the pathology, pathophysiology, MRI appearance and disease control in people with MS, the (differential) diagnosis & monitoring of MS, and investigator-led and commercial clinical trials. He advocates a pro-active treatment approach at all stages of MS.
